Patients and Methods
Abbreviations and Acronyms:AKI (acute kidney injury), AKIN (Acute Kidney Injury Network), CIN (contrast-induced nephropathy), CKD (chronic kidney disease), CT (computed tomographic), eGFR (estimated glomerular filtration rate), EMR (electronic medical record), KDOQI (Kidney Disease Outcomes Quality Initiative), ICD-9 (International Classification of Diseases, Ninth Revision), SCr (serum creatinine)
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
ACR manual on contrast media. Version 9. American College of Radiology website. http://www.acr.org/∼/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast Manual/2013_Contrast_Media.pdf. Accessed June 29, 2015.
- Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines.Eur Radiol. 2011; 21: 2527-2541
- Contrast-induced nephropathy after intravenous administration: fact or fiction?.Radiol Clin North Am. 2009; 47 (v): 789-800
- Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe?.Radiology. 2010; 256: 21-28
- Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis.Radiology. 2013; 267: 119-128
- Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate.Radiology. 2013; 268: 719-728
- Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate.Radiology. 2014; 271: 65-73
- The challenges in assessing contrast-induced nephropathy: where are we now?.AJR Am J Roentgenol. 2014; 202: 784-789
- Quantitating contrast medium-induced nephropathy: controlling the controls.Radiology. 2013; 267: 4-8
- Intravenous contrast material-induced nephropathy: causal or coincident phenomenon?.Radiology. 2013; 267: 106-118
- Intravenous contrast material exposure is not an independent risk factor for dialysis or mortality.Radiology. 2014; 273: 714-725
- Failure of ICD-9-CM codes to identify patients with comorbid chronic kidney disease in diabetes.Health Serv Res. 2006; 41: 564-580
- The use of automated data to identify complications and comorbidities of diabetes: a validation study.J Clin Epidemiol. 1999; 52: 199-207
- Assessing the accuracy of administrative data in health information systems.Med Care. 2004; 42: 1066-1072
- K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.Am J Kidney Dis. 2002; 39: S1-S266
- Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury.Crit Care. 2007; 11: R31
Ridgeway G, McCaffrey DF, Morral AR, Burgette LF, Griffin BA. Toolkit for Weighting and Analysis of Nonequivalent Groups: a tutorial for the TWANG package. http://cran.r-project.org/web/packages/twang/vignettes/twang.pdf. Accessed June 29, 2015.
- R: A Language and Environment for Statistical Computing.([computer program]. Version 3.0.3) R Foundation for Statistical Computing, Vienna, Austria2012
- Acute kidney injury in the critically ill: is iodinated contrast medium really harmful?.Crit Care Med. 2013; 41: 1017-1026
- Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT).Circulation. 2011; 124: 1250-1259
- Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials.PloS One. 2013; 8: e55124
- Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy.Ann Intern Med. 2009; 151: 631-638
Grant Support: The work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under award number K01DK097054. The content is solely the responsibility of the authors and does not necessarily reflect the official views of the National Institutes of Health.
Potential Competing Interests: Drs Williamson and McDonald have received a research grant for Mayo Clinic from GE Healthcare, a manufacturer of the contrast agents studied in this article. The grant did not cover any part of the present study and is not currently active. Dr Kalmes participates on the Cost Effectiveness Board at GE Healthcare, unrelated to contrast nephropathy.